
TRVI Stock Forecast & Price Target
TRVI Analyst Ratings
Bulls say
Trevi Therapeutics Inc is advancing its clinical-stage candidate Haduvio, aimed at addressing chronic cough in adults with idiopathic pulmonary fibrosis and prurigo nodularis, which positions the company in a niche market with significant unmet medical needs. The company's progress in clinical trials will be instrumental in determining its future valuation and potential for success, reflecting the critical nature of data in biotech stock performance. Additionally, maintaining adequate capital is essential for Trevi to continue its operational and developmental plans effectively, which further underscores the importance of financial health in facilitating the advancement of its promising therapies.
Bears say
Trevi Therapeutics faces significant risks related to its clinical trials for Haduvio, as failure to meet trial endpoints or the emergence of safety signals could lead to asset impairment and a decrease in stock value. The company is also operating in highly competitive therapeutic areas, which may hinder its ability to effectively market its products and generate returns on investments. Additionally, Trevi’s anticipated need for capital raises before achieving profitability adds further financial strain and uncertainty to its long-term viability.
This aggregate rating is based on analysts' research of Trevi Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TRVI Analyst Forecast & Price Prediction
Start investing in TRVI
Order type
Buy in
Order amount
Est. shares
0 shares